Pliant Therapeutics, Inc. (PLRX) shareholders
PLRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.70−0.04 (-5.81%)
Close on Nov 13, 2026Market cap $43.16MP/E –Yield 0.00%
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
77.7%
48M of 62M shares
Institutional holders
86
9 new, 13 sold out
Net institutional buying
-2M
In Q2 2026
Insider trades, 12 months
0 buys · 4 sales
Net sold $163.62K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Kevin Tang Joint filing with Tang Capital Management, LLC (9.60%), Tang Capital Partners, LP (5.40%) | 5,859,044 | 9.60% | 13D (active) | Mar 3, 2025 |
| Daniel Schneeberger Joint filing with ADAR1 Capital Management, LLC (8.90%) | 5,509,724 | 8.90% | 13G (passive) | Jun 30, 2026 |
| Deep Track Biotechnology Master Fund, Ltd. Joint filing with Deep Track Capital, LP (6.43%), David Kroin (6.43%) | 3,947,807 | 6.43% | 13G (passive) amendment | Jun 30, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of PLRX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Tang Capital Management LLC | 6,141,261 | 9.92% | $7.00M | −1,871 | 0.32% |
| ADAR1 Capital Management, LLC | 5,509,724 | 8.90% | $6.28M | +2,924,598 | 0.29% |
| Vanguard Capital Management LLC | 2,440,351 | 3.94% | $2.78M | +97,250 | 0.00% |
| Acadian Asset Management LLC | 2,416,508 | 3.90% | $2.75M | – | 0.00% |
| Two Sigma Investments, LP | 2,262,832 | 3.65% | $2.58M | +9,694 | 0.00% |
| Citadel Advisors LLC | 2,142,226 | 3.46% | $2.44M | −1,084,373 | 0.00% |
| Renaissance Technologies LLC | 2,049,874 | 3.31% | $2.34M | +197,032 | 0.00% |
| Monaco Asset Management SAM | 1,938,747 | 3.13% | $2.21M | – | 0.18% |
| Lynx1 Capital Management LP | 1,798,070 | 2.90% | $2.05M | New | 0.24% |
| BML Capital Management, LLC | 1,546,137 | 2.50% | $1.76M | – | 1.00% |
| Prosight Management, LP | 1,370,233 | 2.21% | $1.56M | −297,367 | 0.27% |
| Peapod Lane Capital LLC | 1,309,013 | 2.11% | $1.49M | +20,435 | 1.01% |
| Woodline Partners LP | 1,296,534 | 2.09% | $1.48M | −370,296 | 0.00% |
| BlackRock, Inc. | 1,151,214 | 1.86% | $1.31M | +54,784 | 0.00% |
| Ikarian Capital, LLC | 1,000,000 | 1.61% | $1.14M | New | 0.12% |
| Eversept Partners, LP | 891,425 | 1.44% | $1.02M | – | 0.05% |
| Marshall Wace, Llp | 835,124 | 1.35% | $952.04K | −160,849 | 0.00% |
| Redmile Group, LLC | 772,126 | 1.25% | $880.22K | – | 0.06% |
| JPMorgan Chase & Co | 681,647 | 1.10% | $783.89K | −180,176 | 0.00% |
| Jacobs Levy Equity Management, Inc | 643,120 | 1.04% | $733.16K | −75,423 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 86 | 48M | 77.7% | 9 / 17 | 27 / 13 | 7M | 9M |
| Q1 2026 | 91 | 50M | 80.8% | 14 / 26 | 26 / 16 | 11M | 6M |
| Q4 2025 | 98 | 47M | 76.0% | 15 / 30 | 34 / 13 | 10M | 16M |
| Q3 2025 | 99 | 53M | 85.1% | 12 / 22 | 42 / 26 | 15M | 14M |
| Q2 2025 | 114 | 52M | 83.2% | 24 / 30 | 39 / 50 | 9M | 16M |
| Q1 2025 | 140 | 58M | 93.5% | 33 / 41 | 39 / 50 | 26M | 32M |
| Q4 2024 | 160 | 65M | 100.0% | 23 / 55 | 43 / 13 | 7M | 6M |
| Q3 2024 | 151 | 64M | 100.0% | 24 / 58 | 33 / 16 | 11M | 7M |
| Q2 2024 | 144 | 64M | 100.0% | 28 / 50 | 34 / 18 | 5M | 7M |
| Q1 2024 | 135 | 66M | 100.0% | 18 / 47 | 36 / 16 | 5M | 2M |
| Q4 2023 | 134 | 64M | 100.0% | 19 / 54 | 33 / 20 | 9M | 3M |
| Q3 2023 | 136 | 60M | 97.2% | 21 / 52 | 34 / 28 | 7M | 5M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
26 funds held PLRX in Q2 2026, 69% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of PLRX | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1,746,470 | 2.82% | $1.99M | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 615,799 | 0.99% | $702.01K | 0.00% | Jun 30, 2026 |
| Ultra-Small Company Fund | 471,330 | 0.76% | $537.32K | 0.54% | Jun 30, 2026 |
| iShares Micro-Cap ETF | 206,605 | 0.33% | $235.53K | 0.02% | Jun 30, 2026 |
| Vanguard Health Care Index Fund | 153,162 | 0.25% | $192.98K | 0.00% | May 31, 2026 |
| Fidelity Extended Market Index Fund | 120,873 | 0.20% | $152.30K | 0.00% | May 31, 2026 |
| Invesco RAFI US 1500 Small-Mid ETF | 104,278 | 0.17% | $108.45K | 0.00% | Jul 31, 2026 |
| Goldman Sachs Absolute Return Tracker Fund | 96,072 | 0.16% | $109.52K | 0.00% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 94,752 | 0.15% | $119.39K | 0.00% | May 31, 2026 |
| Ultra-Small Company Market Fund | 82,300 | 0.13% | $93.82K | 0.06% | Jun 30, 2026 |
| Fidelity Series Total Market Index Fund | 79,912 | 0.13% | $100.69K | 0.00% | May 31, 2026 |
| Multi-Manager Small Cap Equity Strategies Fund | 55,129 | 0.09% | $69.46K | 0.01% | May 31, 2026 |
| NVIT Small Cap Value Fund | 50,300 | 0.08% | $57.34K | 0.03% | Jun 30, 2026 |
| Vanguard Institutional Total Stock Market Index Fund | 46,193 | 0.07% | $52.66K | 0.00% | Jun 30, 2026 |
| Vanguard Balanced Index Fund | 31,889 | 0.05% | $36.35K | 0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Bernard Coulie | President and CEO, Director | 914,918 | 1.48% | Apr 17, 2026 |
| David Raben | Chief Medical Officer | – | – | Oct 2, 2026 |
| Minnie Kuo | Chief Operating Officer | 37,806 | 0.06% | Apr 17, 2026 |
| Lily Cheung | Chief Human Resource Officer | 44,847 | 0.07% | Apr 17, 2026 |
| Keith Lamont Cummings | Chief Financial Officer | 297,214 | 0.48% | Apr 17, 2026 |
| Hans Hull | Chief Business Officer | 265,693 | 0.43% | Jan 27, 2025 |
| Eric Lefebvre | Chief Medical Officer | 240,224 | 0.39% | Jan 27, 2025 |
| Mike Ouimette | General Counsel & Corp. Sec'y | 105,544 | 0.17% | Jan 27, 2025 |
| Flavia Borellini | Director | – | – | Jul 13, 2026 |
| Robert Iannone | Director | – | – | Jul 13, 2026 |
| Steve E. Krognes | Director | – | – | Jun 12, 2026 |
| John T. Curnutte | Director | 29,278 | 0.05% | Jun 12, 2026 |
| Darren S. Cline | Director | – | – | Jun 12, 2026 |
| Thomas A. MCCOURT | Director | – | – | Jun 12, 2026 |
| Hoyoung Huh | Director | 239,619 | 0.39% | Jun 12, 2026 |
| Gayle A. Crowell | Director | – | – | Jun 12, 2026 |
| David E. I. Pyott | Director | – | – | Jun 9, 2025 |
| Suzanne Louise Bruhn | Director | 35,081 | 0.06% | Jun 9, 2025 |
| Katharine Knobil | Director | – | – | Jun 9, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Bernard Coulie President and CEO, Director | Jan 20, 2026 | Sale(10b5-1 plan) | −89,375 | $1.28 | $114.40K | 505,601 |
| Lily Cheung Chief Human Resource Officer | Jan 20, 2026 | Sale(10b5-1 plan) | −7,534 | $1.28 | $9.64K | 44,847 |
| Keith Lamont Cummings Chief Financial Officer | Jan 20, 2026 | Sale(10b5-1 plan) | −24,002 | $1.28 | $30.72K | 297,214 |
| Minnie Kuo Chief Operating Officer | Jan 20, 2026 | Sale(10b5-1 plan) | −6,917 | $1.28 | $8.85K | 37,806 |
| Keith Lamont Cummings Chief Financial Officer | Jan 23, 2025 | Award | +56,650 | – | – | 319,258 |
| Mike Ouimette General Counsel & Corp. Sec'y | Jan 23, 2025 | Award | +35,000 | – | – | 105,544 |
| Hans Hull Chief Business Officer | Jan 23, 2025 | Award | +40,150 | – | – | 251,708 |
| Bernard Coulie President and CEO, Director | Jan 23, 2025 | Award | +162,500 | – | – | 593,017 |
| Eric Lefebvre Chief Medical Officer | Jan 23, 2025 | Award | +45,650 | – | – | 240,224 |
| Lily Cheung Chief Human Resource Officer | Jan 23, 2025 | Award | +25,875 | – | – | 50,425 |
| Mike Ouimette General Counsel & Corp. Sec'y | Jan 22, 2025 | Sale(10b5-1 plan) | −10,230 | $10.99 | $112.43K | 70,544 |
| Keith Lamont Cummings Chief Financial Officer | Jan 17, 2025 | Sale(10b5-1 plan) | −20,148 | $11.20 | $225.66K | 262,608 |
| Mike Ouimette General Counsel & Corp. Sec'y | Jan 17, 2025 | Sale(10b5-1 plan) | −13,270 | $11.20 | $148.62K | 80,774 |
| Lily Cheung Chief Human Resource Officer | Jan 17, 2025 | Sale(10b5-1 plan) | −3,740 | $11.20 | $41.89K | 24,550 |
| Eric Lefebvre Chief Medical Officer | Jan 17, 2025 | Sale(10b5-1 plan) | −18,478 | $11.20 | $206.95K | 194,574 |
| Bernard Coulie President and CEO, Director | Jan 17, 2025 | Sale(10b5-1 plan) | −52,419 | $11.20 | $587.09K | 430,517 |
| Hans Hull Chief Business Officer | Jan 17, 2025 | Sale(10b5-1 plan) | −15,936 | $11.20 | $178.48K | 211,558 |
| Bernard Coulie President and CEO, Director | Jul 10, 2024 | Sale(10b5-1 plan) | −38,710 | $11.56 | $447.49K | 482,936 |
| Mike Ouimette General Counsel & Corp. Sec'y | Jul 10, 2024 | Sale(10b5-1 plan) | −7,656 | $11.56 | $88.50K | 94,044 |
| Eric Lefebvre Chief Medical Officer | Jul 10, 2024 | Sale(10b5-1 plan) | −12,319 | $11.56 | $142.41K | 213,052 |
| Keith Lamont Cummings Chief Financial Officer | Jul 10, 2024 | Sale(10b5-1 plan) | −10,911 | $11.56 | $126.13K | 282,115 |
| Hans Hull Chief Business Officer | Jul 10, 2024 | Sale(10b5-1 plan) | −9,900 | $11.56 | $114.44K | 227,494 |
| Bernard Coulie President and CEO, Director | Jul 9, 2024 | Award | +75,625 | – | – | 521,646 |
| Mike Ouimette General Counsel & Corp. Sec'y | Jul 9, 2024 | Award | +14,954 | – | – | 101,700 |
| Eric Lefebvre Chief Medical Officer | Jul 9, 2024 | Award | +24,063 | – | – | 225,371 |
| Keith Lamont Cummings Chief Financial Officer | Jul 9, 2024 | Award | +21,313 | – | – | 293,026 |
| Hans Hull Chief Business Officer | Jul 9, 2024 | Award | +19,337 | – | – | 237,394 |
| Keith Lamont Cummings Chief Financial Officer | May 2, 2024 | Option exercise | +21,000 | $2.08 | $43.68K | 271,713 |
| Eric Lefebvre Chief Medical Officer | Jan 23, 2024 | Award | +42,900 | – | – | 199,820 |
| Mike Ouimette General Counsel & Corp. Sec'y | Jan 23, 2024 | Award | +31,500 | – | – | 86,746 |
| Hans Hull Chief Business Officer | Jan 23, 2024 | Award | +31,500 | – | – | 216,569 |
| Keith Lamont Cummings Chief Financial Officer | Jan 23, 2024 | Award | +55,250 | – | – | 249,855 |
| Lily Cheung Chief Human Resource Officer | Jan 23, 2024 | Award | +26,000 | – | – | 26,795 |
| Bernard Coulie President and CEO, Director | Jan 23, 2024 | Award | +128,150 | – | – | 444,532 |
| Eric Lefebvre Chief Medical Officer | Jan 17, 2024 | Sale(10b5-1 plan) | −10,295 | $17.23 | $177.38K | 156,920 |
| Bernard Coulie President and CEO, Director | Jan 17, 2024 | Sale(10b5-1 plan) | −25,721 | $17.23 | $443.17K | 316,382 |
| Hans Hull Chief Business Officer | Jan 17, 2024 | Sale(10b5-1 plan) | −9,786 | $17.23 | $168.61K | 185,069 |
| Keith Lamont Cummings Chief Financial Officer | Jan 17, 2024 | Sale(10b5-1 plan) | −9,781 | $17.23 | $168.53K | 194,605 |
| Mike Ouimette General Counsel & Corp. Sec'y | Jan 17, 2024 | Sale(10b5-1 plan) | −5,197 | $17.23 | $89.54K | 55,246 |
| Hans Hull Chief Business Officer | Aug 4, 2023 | Option exercise | +8,791 | $2.08 | $18.29K | 214,905 |
| Hans Hull Chief Business Officer | Aug 4, 2023 | Sale(10b5-1 plan) | −20,050 | $20.01 | $401.20K | 194,855 |
| Hans Hull Chief Business Officer | Aug 3, 2023 | Sale(10b5-1 plan) | +1,800 | $20.00 | $36.00K | 206,114 |
| Hans Hull Chief Business Officer | Aug 3, 2023 | Sale(10b5-1 plan) | −13,069 | $20.00 | $261.38K | 206,114 |
| Hans Hull Chief Business Officer | Aug 3, 2023 | Option exercise | +1,800 | $2.08 | $3.74K | 207,914 |
| Mike Ouimette General Counsel & Corp. Sec'y | Jul 20, 2023 | Sale(10b5-1 plan) | −4,755 | $17.55 | $83.45K | 60,443 |
| Hans Hull Chief Business Officer | Jul 17, 2023 | Sale(10b5-1 plan) | −17,937 | $18.01 | $323.05K | 219,183 |
| Eric Lefebvre Chief Medical Officer | Jul 17, 2023 | Sale(10b5-1 plan) | −22,321 | $18.01 | $402.00K | 167,215 |
| Keith Lamont Cummings Chief Financial Officer | Jul 17, 2023 | Sale(10b5-1 plan) | −19,771 | $18.01 | $356.08K | 203,999 |
| Bernard Coulie President and CEO, Director | Jul 17, 2023 | Sale(10b5-1 plan) | −70,150 | $18.01 | $1.26M | 342,103 |
| Mike Ouimette General Counsel & Corp. Sec'y | Jul 17, 2023 | Sale(10b5-1 plan) | −12,778 | $18.01 | $230.13K | 65,198 |
| Mike Ouimette General Counsel & Corp. Sec'y | Jul 14, 2023 | Award | +27,187 | – | – | 77,976 |
| Eric Lefebvre Chief Medical Officer | Jul 14, 2023 | Award | +43,750 | – | – | 189,536 |
| Keith Lamont Cummings Chief Financial Officer | Jul 14, 2023 | Award | +38,750 | – | – | 223,770 |
| Hans Hull Chief Business Officer | Jul 14, 2023 | Award | +35,156 | – | – | 237,120 |
| Bernard Coulie President and CEO, Director | Jul 14, 2023 | Award | +137,500 | – | – | 412,253 |
| Keith Lamont Cummings Chief Financial Officer | Jun 13, 2023 | Option exercise | +30,750 | $2.08 | $63.96K | 185,020 |
| Keith Lamont Cummings Chief Financial Officer | Jun 9, 2023 | Option exercise | +5,800 | $2.08 | $12.06K | 154,270 |
| Mike Ouimette General Counsel & Corp. Sec'y | Apr 3, 2023 | Sale(10b5-1 plan) | −200 | $27.46 | $5.49K | 50,789 |
| Mike Ouimette General Counsel & Corp. Sec'y | Apr 3, 2023 | Sale(10b5-1 plan) | −2,677 | $26.74 | $71.58K | 50,989 |
| Eric Lefebvre Chief Medical Officer | Mar 30, 2023 | Sale(10b5-1 plan) | −11,245 | $26.52 | $298.22K | 145,786 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of float
9.06%
5M shares short
Days to cover
16.2
At 0M shares a day
Change since last report
+5.3%
From 5M shares
Short volume, 20 days
37.6%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Pliant Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 69,303 shares on Aug 20, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Michael Ouimette Officer | Jan 22, 2025 | 10,230 | $113.25K | Jan 22, 2025 | Restricted Stock Units |
| Johannes P Hull Officer | Aug 3, 2023 | 34,919 | $659.97K | Aug 3, 2023 | Exercise of Stock Options |
| Michael Ouimette Officer | Jul 20, 2023 | 4,755 | $84.73K | Jul 20, 2023 | Performance Stock Units |
See a number that looks wrong?